Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice

Hepatology

Volumn 64, Issue 4, 2016, Pages 1072-1085

  Xu, Yang ^a   Li, Fei ^b   Zalzala, Munaf ^a,c   Xu, Jiesi ^a   Gonzalez, Frank J ^b   Adorini, Luciano ^d   Lee, Yoon Kwang ^a   Yin, Liya ^a   Zhang, Yanqiao ^a  

^a Northeastern Ohio Medical University   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF BAGHDAD   (Iraq)

^d INTERCEPT PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; FARNESOID X RECEPTOR; HETERODIMER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; OBETICHOLIC ACID; OXYGENASE; STEROL 12ALPHA HYDROXYLASE; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME INHIBITION; GENE OVEREXPRESSION; LIPID ABSORPTION; LIPID ANALYSIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CHEMISTRY; INTESTINE ABSORPTION; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CHOLESTEROL; INTESTINAL ABSORPTION; MICE; MICE, INBRED C57BL; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84979774653     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28712     Document Type: Article

References (44)

1. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147–191.
2. Zhang Y. Farnesoid X receptor—acting through bile acids to treat metabolic disorders. Drugs Future 2010;35:635–641.
3. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015;21:159–165.
4. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006;103:1006–1011.
5. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145:574–582.e1.
6. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102–1109.
7. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol 2013;86:1517–1524.
8. Zhang Y, Yin L, Anderson J, Ma H, Gonzalez FJ, Willson TM, Edwards PA. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J Biol Chem 2010;285:3035–3043.
9. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006;113:2548–2555.
10. Rosenson RS, Brewer HB, Jr., Davidson WS, Fayad ZA, Fuster V, Goldstein J, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012;125:1905–1919.
11. −/− mice. J Lipid Res 2009;50:1090–1100.
12. Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem 2009;52:904–907.
13. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol 2013;86:1517–1524.
14. Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett 2008;582:10–18.
15. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 2012;53:1723–1737.
16. Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 2003;278:104–110.
17. Kinoshita M, Fujita M, Usui S, Maeda Y, Kudo M, Hirota D, et al. Scavenger receptor type BI potentiates reverse cholesterol transport system by removing cholesterol ester from HDL. Atherosclerosis 2004;173:197–202.
18. van der Velde AE, Groen AK. Shifting gears: liver SR-BI drives reverse cholesterol transport in macrophages. J Clin Invest 2005;115:2699–2701.
19. Wang J, Mitsche MA, Lutjohann D, Cohen JC, Xie XS, Hobbs HH. Relative roles of ABCG5/ABCG8 in liver and intestine. J Lipid Res 2015;56:319–330.
20. Huang Y, Wang J, Quan G, Wang X, Yang L, Zhong L. Lactobacillus acidophilus ATCC 4356 prevents atherosclerosis via inhibition of intestinal cholesterol absorption in apolipoprotein E-knockout mice. Appl Environ Microbiol 2014;80:7496–7504.
21. Davidson MH, Voogt J, Luchoomun J, Decaris J, Killion S, Boban D, et al. Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis 2013;230:322–329.
22. Wang DQ, Tazuma S, Cohen DE, Carey MC. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am J Physiol Gastrointest Liver Physiol 2003;285:G494–G502.
23. Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006;31:572–580.
24. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000;102:731–744.
25. Wang L, Lee YK, Bundman D, Han Y, Thevananther S, Kim CS, et al. Redundant pathways for negative feedback regulation of bile acid production. Dev Cell 2002;2:721–731.
26. Pandak WM, Schwarz C, Hylemon PB, Mallonee D, Valerie K, Heuman DM, et al. Effects of CYP7A1 overexpression on cholesterol and bile acid homeostasis. Am J Physiol Gastrointest Liver Physiol 2001;281:G878–G889.
27. Pandak WM, Bohdan P, Franklund C, Mallonee DH, Eggertsen G, Bjorkhem I, et al. Expression of sterol 12alpha-hydroxylase alters bile acid pool composition in primary rat hepatocytes and in vivo. Gastroenterology 2001;120:1801–1809.
28. Zhang Y, Yin L, Hillgartner FB. SREBP-1 integrates the actions of thyroid hormone, insulin, cAMP, and medium-chain fatty acids on ACCalpha transcription in hepatocytes. J Lipid Res 2003;44:356–368.
29. Xu J, Li Y, Chen W, Xu Y, Yin L, Ge X, et al. Hepatic carboxylesterase 1 is essential for both normal and farnesoid X-receptor-controlled lipid homeostasis. Hepatology 2014;59:1761–1771.
30. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911–917.
31. Xu Y, Zalzala M, Xu J, Li Y, Yin L, Zhang Y. A metabolic stress-inducible miR-34a-HNF4alpha pathway regulates lipid and lipoprotein metabolism. Nat Commun 2015;6:7466.
32. Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, Cai J, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015;125:386–402.
33. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006;113:90–97.
34. Turley SD, Herndon MW, Dietschy JM. Reevaluation and application of the dual-isotope plasma ratio method for the measurement of intestinal cholesterol absorption in the hamster. J Lipid Res 1994;35:328–339.
35. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217–225.
36. Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 2012;56:1034–1043.
37. Kerr TA, Saeki S, Schneider M, Schaefer K, Berdy S, Redder T, et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev Cell 2002;2:713–720.
38. Brufau G, Groen AK, Kuipers F. Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion. Arterioscler Thromb Vasc Biol 2011;31:1726–1733.
39. −/− mice versus hamsters. J Lipid Res 2013;54:1283–1299.
40. Jove M, Ayala V, Ramirez-Nunez O, Serrano JC, Cassanye A, Arola L, et al. Lipidomic and metabolomic analyses reveal potential plasma biomarkers of early atheromatous plaque formation in hamsters. Cardiovasc Res 2013;97:642–652.
41. Schwarz M, Russell DW, Dietschy JM, Turley SD. Alternate pathways of bile acid synthesis in the cholesterol 7alpha-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding. J Lipid Res 2001;42:1594–1603.
42. Erickson SK, Lear SR, Deane S, Dubrac S, Huling SL, Nguyen L, et al. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J Lipid Res 2003;44:1001–1009.
43. Li-Hawkins J, Gafvels M, Olin M, Lund EG, Andersson U, Schuster G, et al. Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J Clin Invest 2002;110:1191–1200.
44. Slatis K, Gafvels M, Kannisto K, Ovchinnikova O, Paulsson-Berne G, Parini P, et al. Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice. J Lipid Res 2010;51:3289–3298.